Wipro Limited has announced a partnership with Hyderabad based Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI).

This partnership combines Transcell’s innovative stem cell technology with the advanced augmented intelligence capabilities of Wipro HOLMES^® to improve the safety of global vaccine immunization programs.
 
By applying AI to the vaccine development process, our solution is capable of predicting adverse neurovirulent impacts resulting from vaccinations.

Currently, vaccine safety assessment often includes testing on animals to measure adverse impacts.  Using Wipro HOLMES^® instead, researchers and biopharmaceutical companies have a new and fully viable solution and alternative.

Wipro HOLMES^® can also be integrated into any existing workflow, including quality control tests in vaccine production, batchwise release and other safety evaluation assays.
 
This partnership will also expand the Wipro HOLMES^® solutions available to life science companies. The solution applies AI for drug repurposing and Messenger Ribonucleic Acid (mRNA) based platform for biodefense. It enables the testing of new vaccines by applying augmented intelligence to stem cell research and measuring safety and potency.

This is the first in a series of next generation solutions that the partnership will offer to determine the safety and efficacy of a wide-range of products from vaccines to prescription medications, cosmetics and more.